Analysts, paid bashers, and shorts will try to convince you that IMGN is not worth #$%$ prior to Feb 26th T-DM1 decision date. You get discouraged, panic, and sell. Bashers tells you somehow, the current price already figures in T-DM1 approval....If you think about it...how so???? How to they know how much revenue T-DM1 can bring in, how do they know the impact a vaildated TAP technology has on the rest of IMGN pipeline, how do they know what potential partnerships or acquisition possibilites is coming down ? The answer is ...THEY DON''T. Since the Oppenheimer analysts downgraded IMGN to $14, IMGN have already lost 8% of its value. I just cannot see how IMGN will stay flat when T-DM1, a potential billion dollar blockbuster will get approved and an army of Genentech reps will be promoting this billion dollar drug. The reality is also that many physicians will be using T-DM1 as a first line agent well before completion of Marianne trial because T-DM1 saves lives. I don't know about you, but a cancer patient may not want to wait for failure before reaching for T-DM1. Potentially, T-DM1 sales can far exceed analyst's expecatations....Oh...wait...current price also does not reflect European approval...... IMGN long and strong...don't let shorts and bashers frazzle your nerves.